Quick Dispatch:
Your tirzepatide surmount 4 Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your tirzepatide surmount 4 Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial ships.
Need Help?
Questions about tirzepatide surmount 4 Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for tirzepatide surmount 4 Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial in your area.
🔬 Breaking Down the SURMOUNT-4 Study on Tirzepatide 🔍, Today’s spotlight: JAMA’s publication of the SURMOUNT-4 study results on tirzepatide, known for its use in diabetes treatments Mounjaro and AOM
23.88
SURMOUNT‐4 study design. This is a phase 3, multicenter, randomized,
20.71
SURMOUNT-1 Trial
28.63
Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial
27.40
Tirzepatide lowers body weight for adults with obesity, regardless of disease duration
26.95
In the SURMOUNT-4 trial, 82.5% of adults with obesity regained ≥25% of initial weight lost within one year of tirzepatide withdrawal; most showed reversal of cardiometabolic improvements. https://bit.ly/4rBMZgh
23.02
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
25.57
